OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Dobinson, Hazel C.; Gibani, Malick M.; Jones, Claire; Thomaides-Brears, Helena B.; Voysey, Merryn; Darton, Thomas C.; Waddington, Claire S.; Campbell, Danielle; Milligan, Iain; Zhou, Liqing; Shrestha, Sonu; Kerridge, Simon A.; Peters, Anna; Stevens, Zoe; Podda, Audino; Martin, Laura B.; D’Alessio, Flavia; Thanh, Duy Pham; Basnyat, Buddha; Baker, Stephen; Angus, Brian; Levine, Myron M.; Blohmke, Christoph J.; Pollard, Andrew J. (2017)
Publisher: Oxford University Press
Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Languages: English
Types: Article
Subjects: enteric fever, Salmonella enterica paratyphi A, Major Article, paratyphoid infection, human challenge study, Editor's Choice, immune responses
Background.\ud \ud To expedite the evaluation of vaccines against paratyphoid fever, we aimed to develop the first human challenge model of Salmonella enterica serovar Paratyphi A infection.\ud Methods.\ud \ud Two groups of 20 participants underwent oral challenge with S. Paratyphi A following sodium bicarbonate pretreatment at 1 of 2 dose levels (group 1: 1–5 × 103 colony-forming units [CFU] and group 2: 0.5–1 × 103 CFU). Participants were monitored in an outpatient setting with daily clinical review and collection of blood and stool cultures. Antibiotic treatment was started when prespecified diagnostic criteria were met (temperature ≥38°C for ≥12 hours and/or bacteremia) or at day 14 postchallenge.\ud Results.\ud \ud The primary study objective was achieved following challenge with 1–5 × 103 CFU (group 1), which resulted in an attack rate of 12 of 20 (60%). Compared with typhoid challenge, paratyphoid was notable for high rates of subclinical bacteremia (at this dose, 11/20 [55%]). Despite limited symptoms, bacteremia persisted for up to 96 hours after antibiotic treatment (median duration of bacteremia, 53 hours [interquartile range, 24–85 hours]). Shedding of S. Paratyphi A in stool typically preceded onset of bacteremia.\ud Conclusions.\ud \ud Challenge with S. Paratyphi A at a dose of 1–5 × 103 CFU was well tolerated and associated with an acceptable safety profile. The frequency and persistence of bacteremia in the absence of clinical symptoms was notable, and markedly different from that seen in previous typhoid challenge studies. We conclude that the paratyphoid challenge model is suitable for the assessment of vaccine efficacy using endpoints that include bacteremia and/or symptomatology.\ud Clinical Trials Registration.\ud \ud NCT02100397.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Arndt MB, Mosites EM, Tian M, et al. Estimating the burden of paratyphoid a in Asia and Africa. PLoS Negl Trop Dis 2014; 8:e2925.
    • 2. Gunn JS, Marshall JM, Baker S, Dongol S, Charles RC, Ryan ET. Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence. Trends Microbiol 2014; 22:648-55.
    • 3. McClelland M, Sanderson KE, Clifton SW, et al. Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid. Nat Genet 2004; 36:1268-74.
    • 4. Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol 2012; 19:825-34.
    • 5. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin Infect Dis 2007; 45(suppl 1):S24-8.
    • 6. Martin LB, Simon R, MacLennan CA, Tennant SM, Sahastrabuddhe S, Khan MI. Status of paratyphoid fever vaccine research and development. Vaccine 2016; 34:2900-2.
    • 7. Darton TC, Blohmke CJ, Moorthy VS, et  al. Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infect Dis 2015; 15:840-51.
    • 8. England PH. Enteric fever (typhoid and paratyphoid) in England, Wales and Northern Ireland: 2014. 2015. Available at: uploads/system/uploads/attachment_data/file/488395/Enteric_fever_annual_ report_2014_FINAL_.pdf. Accessed 1 January 2016.
    • 9. McCullagh D, Dobinson HC, Darton T, et al. Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers. BMJ Open 2015; 5:e007481.
    • 10. Balasegaram S, Potter AL, Grynszpan D, et al; Typhoid and Paratyphoid Reference Group, Health Protection Agency, London, England. Guidelines for the public health management of typhoid and paratyphoid in England: practice guidelines from the National Typhoid and Paratyphoid Reference Group. J Infect 2012; 65:197-213.
    • 11. Waddington CS, Darton TC, Jones C, et al. An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis 2014; 58:1230-40.
    • 12. The R Core team. R: a language and environment for statistical computing. Available at: Accessed 30 September 2016.
    • 13. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med 2002; 347:1770-82.
    • 14. Wain J, Diep TS, Ho VA, et al. Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol 1998; 36:1683-7.
    • 15. Proescher F. A report of forty-eight new cases of paratyphoid fever (type A). J Am Med Assoc 1909; LII:470. Available at: aspx?articleid=428987. Accessed 26 March 2016.
    • 16. Dong BQ, Yang J, Wang XY, et al. Trends and disease burden of enteric fever in Guangxi province, China, 1994-2004. Bull World Health Organ 2010; 88:689-96.
    • 17. Bodhidatta L, Taylor DN, Thisyakorn U, Echeverria P. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev Infect Dis 1987; 9:841-5.
    • 18. World Health Organization. Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser 2014; 1-266.
    • 19. Maskey AP, Day JN, Phung QT, et  al. Salmonella enterica serovar Paratyphi A  and S.  enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006; 42:1247-53.
    • 20. Vollaard AM, Ali S, Widjaja S, et al. Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. Trans R Soc Trop Med Hyg 2005; 99:440-50.
    • 21. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ. Typhoid fever: pathogenesis and immunologic control. N Engl J Med 1970; 283:686-91.
    • 22. Bainbridge FA. paratyphoid fever and meat poisoning. Lancet 1912; 704-9.
    • 23. Grattan W, Wood L. Paratyphoid fever in India. JR Army Med Corps 1911; 143-56.
    • 24. Safford AH. Paratyphoid fever. An account of two epidemics with remarks on some clinical features of the disease. JR Army Med Corps 1912; 20:567-78.
    • 25. Clinical Laboratory and Standards Institute. Performance standards for antimicrobial susceptibility testing: 24th informational supplement. Wayne, PA; CLSI, 2014.
    • 26. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Växjö, Sweden: EUCAST, 2016; 0-77.
    • 27. Zhou Z, McCann A, Weill FX, et al. Transient Darwinian selection in Salmonella enterica serovar Paratyphi A  during 450  years of global spread of enteric fever. Proc Natl Acad Sci U S A 2014; 111:12199-204.
  • No similar publications.
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok